87474-15-5

Usage

Uses

Used in Pharmaceutical Research:
2,3-Dihydro-1,4-benzodioxine-5-sulfonyl chloride, 97% is used as a reagent for the introduction of the benzodioxine-5-sulfonyl chloride group into organic molecules for the development of new pharmaceuticals. Its high reactivity and stability make it a valuable tool in the synthesis of bioactive compounds for research purposes.
Used in Agrochemical Production:
2,3-Dihydro-1,4-benzodioxine-5-sulfonyl chloride, 97% is used as a reagent in the production of agrochemicals, where the benzodioxine-5-sulfonyl chloride group can be incorporated into molecules to enhance their biological activity and effectiveness in agricultural applications.
Used in Organic Synthesis:
2,3-Dihydro-1,4-benzodioxine-5-sulfonyl chloride, 97% is used as a versatile reagent in organic synthesis for the modification of various functional groups. Its high reactivity allows for the creation of new compounds with potential applications in various industries, including pharmaceuticals, agrochemicals, and materials science.

Upstream product

• 14381-51-2 3-bromo-1,2-dihydroxybenzene 
• 58328-39-5 5-bromo-2,3-dihydrobenzo[1,4]dioxin 

Downstream Products

• 1338576-60-5 5-[1,1-dimethyl-2-(4-methoxyphenyl)-1H-inden-3-yl]-2,3-dihydro-1,4-benzodioxine 
• 881677-23-2 1-(2,3-dihydro-1,4-benzodioxin-5-ylsulfonyl)-4-methyl-5-phenyl-1H-pyrrole-3-carbaldehyde 

Relevant academic research and scientific papers

COMBINATION PRODUCT FOR THE TREATMENT OF CANCEROUS DISEASES

The present invention relates to a product for combination therapies useful for the treatment of cancer diseases. In particular, the invention relates to the combination of an anti-PD-Ll antibody and an MCT4 inhibitor of Formula (I). The therapeutic combination may be utilized for the use in treating a subject having a cancer disease that tests positive for PD-L1 and/or MCT4 expression.

DISUBSTITUTED ALKYNE DERIVATIVES

The present invention relates to disubstituted alkyne derivatives. These compounds are useful for the prevention and/or treatment of several medical conditions including hyperproliferative disorders and diseases.

CONDENSED HETEROCYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY

The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I) wherein R1, A, B, D, E, G, Q, Ar, n, m, and p are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

4'-AMINO CYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY

The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): formula (I) wherein Cy is selected from formula (Il) and wherein R1, R2, R3, Q, G, Ar, m, n and p are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

3' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY

The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): wherein Q, R1, R4, m and Ar are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

Aromatic heterocyclic derivatives as enzyme inhibitors

The present invention discloses peptide aldehydes which are potent and specific inhibitors of thrombin, their pharmaceutically acceptable salts, pharmaceutically acceptable compositions thereof, and methods of using them as therapeutic agents for disease states in mammals characterized by abnormal thrombosis.